Biotechnology(IN00261.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Biotechnology
IN00261.US
News
View More

US FDA places clinical hold on Regenxbio's gene therapy trials

Jan 28 (Reuters) - Regenxbio ( RGNX ) said on ‌Wednesday the U.S. ​Food and ‍Drug ⁠Administration ⁠has placed ‌a ​clinical hold on two ⁠of ‍its ​experimental gene therapy programs ‍for rare childhood diseases after ​a ‍brain tumor was ​found in one treated patient. (Reporting by Padmanabhan ​Ananthan in Bengaluru; Editing ‍by Shailesh Kuber)

fidelity·
US
BIB
+1.15%
US
IBB
+0.60%
US
FBT
-0.04%
fidelity·
US
BIB
+1.15%
US
IBB
+0.60%
US
FBT
-0.04%

Biomind Labs Inc. Trading Resumes on Cboe Canada

Trading in Biomind Labs Inc. (Cboe CA: BMND) will resume at 8:00 AM ET after a temporary suspension by the Canadian Investment Regulatory Organization (CIRO).

Reuters·
US
XBI
+0.52%
US
ARKG
-0.18%
US
PBE
-0.06%
Reuters·
US
XBI
+0.52%
US
ARKG
-0.18%
US
PBE
-0.06%

Aditxt, Inc. Granted Nasdaq Compliance Extension

On January 27, 2026, Aditxt, Inc. received an extension from Nasdaq to regain compliance with listing rules. Key Highlights: Nasdaq requires $2.5M equity or $35M market value.Extension conditional on financing by May 15, 2026.Failure to comply by June 30, 2026, may lead to delisting.Company can appeal any delisting decision.Original SEC Filing: Aditxt, Inc. [ ADTX ] - 8-K - Jan. 28, 2026DisclaimerThis is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

TradingView·
US
NDAQ
-0.39%
US
ADTX
+6.63%
TradingView·
US
NDAQ
-0.39%
US
ADTX
+6.63%

Ensysce Biosciences Reaches Key Enrollment Milestone in Phase 3 Trial of PF614 for Acute Pain

Ensysce Biosciences Inc. has reached a key milestone in its Phase 3 clinical trial of PF614, with 50% enrollment of targeted subjects for interim review. The trial, PF614-301, is a multicenter, randomized, double-blind, placebo-controlled study assessing PF614's efficacy and safety for treating moderate to severe pain post-abdominoplasty. Enrollment began in December 2025 at three U.S. sites, with interim results expected in the future. This news is generated by Public Technologies and should not be considered financial or legal advice.

Reuters·
US
IBB
+0.60%
US
XBI
+0.52%
US
ENSC
-4.31%
Reuters·
US
IBB
+0.60%
US
XBI
+0.52%
US
ENSC
-4.31%

Renewal Fuels Inc. Changes Name to American Fusion

Renewal Fuels Inc. has officially changed its name to American Fusion Inc. as part of its regulatory and corporate initiatives. This announcement highlights the company's ongoing efforts to rebrand and align with its strategic goals.

Reuters·
US
IBB
+0.60%
US
PBE
-0.06%
US
SBIO
+1.01%
Reuters·
US
IBB
+0.60%
US
PBE
-0.06%
US
SBIO
+1.01%
Posts
View More
© 2026 Longbridge｜Disclaimer